Mesh Bio, a Singapore-based health deep tech startup in transforming chronic disease management through predictive analytics, has raised an undisclosed amount of funding from East Ventures, a pioneering and leading sector-agnostic venture capital firm focusing on Southeast Asia.

The funding will be allocated to further develop the digital twin technologies in chronic disease management and to expand its services across Southeast Asia, mainly Indonesia, Malaysia, and the Philippines. Founded in 2018 by (left in the image) Andrew Wu (Co-Founder and Chief Executive Officer) and (right in the image) Arsen Batagov (Co-Founder and Chief Technology Officer), Mesh Bio has the vision to deliver cutting-edge digital solutions to address challenges in patient management and rising chronic diseases in the region. 

Mesh Bio presents cutting-edge digital solutions to address challenges in patient management and rising chronic diseases in the region. Mesh Bio's Health Intelligence Platform, named DARA, provides real-time, multidimensional patient data, which includes health history, lab tests, and medical images. DARA delivers a patient-centric visual report, helping doctors counsel patients and allowing patients to understand their laboratory reports and the diseases they live with.

Based on the data, DARA provides predictive analytics to identify patients at risk of chronic diseases for earlier diagnosis and treatment. Moreover, DARA also enables doctors to leverage knowledge from the global community of healthcare practitioners according to clinical best practices, guidelines, and holistic patient assessments.